Identification of the mechanism of sensitization of human ovarian cancer cells to anticancer drugs by the DNA double strand breaks inhibitors

2016/23/N/NZ7/02023

Keywords

Descriptors

  • NZ7_14: Farmacja, farmakoterapia, farmakologia

Panel

NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution

Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

Voivodeship: łódzkie

Other projects carried out by the institution »

Principal investigator (from the host institution)

Anna Macieja

Number of co-investigators in the project: 2

Call

PRELUDIUM 12 – announced on 2016-09-15

Amount awarded
148 800 PLN
Project start date
2017-10-12
Project end date
2021-10-11
Project duration
48 months (the same as in the proposal)
Project status
Project settled

Project description

Download the project description in a pdf file

Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

Publication in academic press/journals (1)

  1. DNA Double-Strand Break Repair Inhibitors: YU238259, A12B4C3 and DDRI-18 Overcome the Cisplatin Resistance in Human Ovarian Cancer Cells, but Not under Hypoxia Conditions

    Authors:
    Anna Macieja, Izabela Gulbas, Tomasz Popławski
    Academic press:
    Current Issues in Molecular Biology (year: 2023, volume: 45(10), pages: 7915-7932), Publisher: MDPI (Multidisciplinary Digital Publishing Institute)
    Status:
    Published
    DOI:
    10.3390/cimb45100500 – link to the publication

« New search

Graphic design and implementation: Jakub Piotrowski